explore -WSS

explore

author：Wikipedia 2025-09-30 06:20:11 - browse：12413

Christine Kao/STAT

The Food and Drug Administration’s approval on Friday of two gene therapies for sickle cell disease sets up what could be an intense competition between Bluebird Bio, maker of Lyfgenia, and the partnership of Vertex Pharmaceuticals and CRISPR Therapeutics, whose drug is Casgevy.

For the first time, physicians and patients will have a choice of potentially curative treatments for an inherited disease that affects nearly 100,000 Americans.

The Vertex/CRISPR team would seem to have the edge. As the first CRISPR-based therapy, Casgevy has the advantage of being powered by the latest and buzziest biological technology, though some physicians and patients may be more comfortable with the lentiviral vector technology behind Lyfgenia, which dates back to the 1990s — even with a “black box” warning of a risk of blood cancer added to its label.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Covid’s new normal has set in amid another rise in cases

entertainment

WSS

Gene editing the human germline: What are the risks?

Medicare to pay more for cardiac rehab in hospital outpatient clinics

Intermittent fasting comes with a heart risk? Not so fast

Orchard's therapy for neuron disease in children wins FDA approval

Neurocrine congenital adrenal hyperplasia trial succeeds

FDA weighs limits of animal data in assessing artificial wombs

focus

explore

knowledge

In Memoriam: Notable people who died in 2023

Stop the failed accountable care organization experiment

Malaria cases in Florida and Texas: Here’s what you need to know

People with substance use disorder deserve online privacy

Walensky prepares to leave CDC — and Congress — behind

U.K. researchers warn about biases in medical devices, algorithms

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Apple is now the first public company to be valued at $3 trillion

White House Covid adviser calls on docs to combat misinformation

Wikipedia

Neuroscience’s long legacy of racism

Stop the failed accountable care organization experiment

Health AI adoption puts security, privacy startups on investors' radar

Asbestos, a deadly carcinogen, banned by EPA

Eli Lilly CEO gives to Mike Pence presidential super PAC

Akili changes sales model for its ADHD video game treatment

entertainment

entertainment

leisure time

entertainment